Singapore, Jan. 8 -- US-based startupXellar Biosystems, a globally leading innovator in next-generation artificial intelligence (AI)- and computer vision-assisted, organ-on-a-chip-based drug discovery and development platforms, has entered into a multi-year strategic collaboration agreement with Woojung BioCo., a Korea-listed biotechnology company with strong capabilities in translational research and life sciences services.

Through this collaboration, the two companies will work together to integrate their complementary technologies and expertise to advance innovative, human-relevant research solutions in the life sciences field. Xellar will contribute its AI-enabled organ-on-a-chip platform, computer vision-based analysis pipelines, an...